"With $8.8 million of funding from the National Institutes of Health (NIH) and outstanding strategic development and regulatory support from Cato Research Ltd., we have successfully completed the required studies enabling Phase 2 clinical development of AV-101 for multiple large market neurological diseases and conditions. In addition, recent data from the NIH suggest that the same neural pathway modified by AV-101 may be useful for treating depression. Launching a broad strategic collaboration to advance development and commercialization of AV-101 is among our key goals in 2013."
Just showcasing the Financial Backers (NIH....NIH). Not many smallcap otcbb biotechs have what $VSTA has going. Keep it marked for more news.
News 
Market Data 
Discover 
